| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7094427 | IMPAX LABS INC | Combination immediate release controlled release levodopa/carbidopa dosage forms |
May, 2022
(1 year, 10 months ago) | |
| US9463246 | IMPAX LABS INC | Controlled release formulations of levodopa and uses thereof |
Dec, 2028
(4 years from now) | |
| US8377474 | IMPAX LABS INC | Controlled release formulations of levodopa and uses thereof |
Dec, 2028
(4 years from now) | |
| US8557283 | IMPAX LABS INC | Controlled release formulations of levodopa and uses thereof |
Dec, 2028
(4 years from now) | |
| US8454998 | IMPAX LABS INC | Controlled release formulations of levodopa and uses thereof |
Dec, 2028
(4 years from now) | |
| US9533046 | IMPAX LABS INC | Controlled release formulations of levodopa and uses thereof |
Dec, 2028
(4 years from now) | |
| US9901640 | IMPAX LABS INC | Controlled release formulations of levodopa and uses thereof |
Dec, 2028
(4 years from now) | |
| US9089607 | IMPAX LABS INC | Controlled release formulations of levodopa and uses thereof |
Dec, 2028
(4 years from now) | |
| US9089608 | IMPAX LABS INC | Controlled release formulations of levodopa and uses thereof |
Dec, 2028
(4 years from now) | |
Rytary is owned by Impax Labs Inc.
Rytary contains Carbidopa; Levodopa.
Rytary has a total of 9 drug patents out of which 1 drug patent has expired.
Expired drug patents of Rytary are:
- US7094427
Rytary was authorised for market use on 07 January, 2015.
Rytary is available in capsule, extended release;oral dosage forms.
Rytary can be used as treatment of parkinsonism that may follow carbon monoxide intoxication or manganese intoxication, treatment of parkinson's disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication, treatment of parkinson's disease, method of providing a therapeutically effective and stable median blood plasma level of levodopa.
The generics of Rytary are possible to be released after 26 December, 2028.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Jan 07, 2018 |
Drugs and Companies using CARBIDOPA; LEVODOPA ingredient
Market Authorisation Date: 07 January, 2015
Treatment: Treatment of parkinson's disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication; Treatment of parkinson's disease; Treatment o...
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
RYTARY family patents
